---
layout: default
title: Atezolizumab
description: "Atezolizumab çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚é«˜è­‰æ“šç­‰ç´š L1ï¼ŒåŒ…å« 10 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: é«˜è­‰æ“šç­‰ç´š (L1-L2)
nav_order: 25
evidence_level: L3
indication_count: 10
---

# Atezolizumab

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L1</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>10</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Atezolizumabï¼šå¾è‚ºç™Œå…ç–«æ²»ç™‚åˆ°æ³Œå°¿é“ä¸Šçš®ç™Œ

## ä¸€å¥è©±ç¸½çµ
<p class="key-answer" data-question="Atezolizumab å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Atezolizumab æ˜¯ PD-L1 å…ç–«æª¢æŸ¥é»æŠ‘åˆ¶åŠ‘ï¼Œç›®å‰ç”¨æ–¼éå°ç´°èƒè‚ºç™Œã€å°ç´°èƒè‚ºç™Œã€ä¸‰é™°æ€§ä¹³ç™Œã€è‚ç´°èƒç™Œç­‰ï¼ŒTxGNN é æ¸¬å…¶å¯èƒ½å°æ”è­·è…ºå°¿é“æ³Œå°¿ä¸Šçš®ç™Œæœ‰æ•ˆã€‚
</p>

## å¿«é€Ÿç¸½è¦½
| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | éå°ç´°èƒè‚ºç™Œã€ä¸‰é™°æ€§ä¹³ç™Œã€å°ç´°èƒè‚ºç™Œã€è‚ç´°èƒç™Œã€è‚ºæ³¡ç‹€è»Ÿçµ„ç¹”è‚‰ç˜¤ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | prostatic urethra urothelial carcinomaã€kidney pelvis sarcomatoid transitional cell carcinomaã€infiltrating bladder urothelial carcinoma sarcomatoid variantã€renal pelvis papillary urothelial carcinomaã€transitional cell carcinomaã€uterine ligament adenocarcinomaã€endocervical carcinomaã€adenoid cystic carcinoma of the cervix uteriã€uterine ligament serous adenocarcinomaã€signet ring cell variant cervical mucinous adenocarcinoma |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.98% |
| è­‰æ“šç­‰ç´š | L1 (å¤šå€‹ Phase 3 è‡¨åºŠè©¦é©—é€²è¡Œä¸­) |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | 2 (æ³¨å°„åŠ‘ã€çš®ä¸‹æ³¨å°„åŠ‘) |
| å»ºè­°æ±ºç­– | Proceed |



## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. prostatic urethra urothelial carcinoma</span>
<span class="evidence-badge evidence-L3">L3</span>
<span class="prediction-score">99.98%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content">

<h3>ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ</h3>

<p><p class="key-answer" data-question="é€™å€‹è—¥ç‰©çš„ä½œç”¨æ©Ÿè½‰æ˜¯ä»€éº¼ï¼Ÿ"></p>
<p>Atezolizumab é€éé˜»æ–· PD-L1 èˆ‡ PD-1 çš„çµåˆï¼Œè§£é™¤è…«ç˜¤å° T ç´°èƒçš„å…ç–«æŠ‘åˆ¶ï¼Œå¢å¼·æŠ—è…«ç˜¤å…ç–«åæ‡‰ã€‚æ³Œå°¿ä¸Šçš®ç™Œæ˜¯å·²çŸ¥å°å…ç–«æª¢æŸ¥é»æŠ‘åˆ¶åŠ‘æœ‰åæ‡‰çš„è…«ç˜¤é¡å‹ï¼ŒFDA å·²æ ¸å‡†å…¶ä»– PD-1/PD-L1 æŠ‘åˆ¶åŠ‘ç”¨æ–¼è†€èƒ±ç™Œç­‰æ³Œå°¿ä¸Šçš®ç™Œã€‚æ”è­·è…ºå°¿é“æ³Œå°¿ä¸Šçš®ç™Œèˆ‡è†€èƒ±æ³Œå°¿ä¸Šçš®ç™ŒåŒæºï¼Œé æœŸå…·æœ‰ç›¸ä¼¼çš„å…ç–«å¾®ç’°å¢ƒï¼Œå› æ­¤ atezolizumab å°æ­¤é©æ‡‰ç—‡çš„é æ¸¬å…·æœ‰ç”Ÿç‰©å­¸åˆç†æ€§ã€‚</p>
<p></p></p>

<p><div class="key-takeaway"></p>
<p>æ­¤é æ¸¬åŸºæ–¼è—¥ç‰©çš„ä½œç”¨æ©Ÿè½‰ï¼Œèˆ‡ç¾æœ‰è‡¨åºŠè­‰æ“šæ–¹å‘ä¸€è‡´ã€‚</p>

<h3>è‡¨åºŠè©¦é©—</h3>

<table>
<thead>
<tr>
<th>è©¦é©—ç·¨è™Ÿ</th>
<th>éšæ®µ</th>
<th>ç‹€æ…‹</th>
<th>æ”¶æ¡ˆäººæ•¸</th>
<th>ä¸»è¦ç™¼ç¾</th>
</tr>
</thead>
<tbody>
<tr>
<td><a href="https://clinicaltrials.gov/study/NCT04660344">NCT04660344</a></td>
<td>Phase 3</td>
<td>é€²è¡Œä¸­</td>
<td>761</td>
<td>ctDNA é™½æ€§é«˜é¢¨éšªè‚Œè‚‰ä¾µçŠ¯æ€§è†€èƒ±ç™Œè¡“å¾Œè¼”åŠ©æ²»ç™‚</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/study/NCT03775265">NCT03775265</a></td>
<td>Phase 3</td>
<td>é€²è¡Œä¸­</td>
<td>475</td>
<td>å±€éƒ¨è‚Œè‚‰ä¾µçŠ¯æ€§è†€èƒ±ç™Œåˆä½µåŒ–æ”¾ç™‚è©•ä¼°</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/study/NCT03237780">NCT03237780</a></td>
<td>Phase 2</td>
<td>é€²è¡Œä¸­</td>
<td>72</td>
<td>å¾©ç™¼æ€§è½‰ç§»æ€§æ³Œå°¿ä¸Šçš®ç™Œåˆä½µ Eribulin</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/study/NCT03170960">NCT03170960</a></td>
<td>Phase 1b</td>
<td>é€²è¡Œä¸­</td>
<td>914</td>
<td>Cabozantinib åˆä½µ atezolizumab ç”¨æ–¼æ³Œå°¿ä¸Šçš®ç™Œç­‰å¤šç¨®å¯¦é«”è…«ç˜¤</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/study/NCT02844816">NCT02844816</a></td>
<td>Phase 2</td>
<td>å·²å®Œæˆ</td>
<td>172</td>
<td>BCG ç„¡æ•ˆä¹‹éè‚Œè‚‰ä¾µçŠ¯æ€§è†€èƒ±ç™Œä½¿ç”¨ atezolizumab</td>
</tr>
</tbody>
</table>

<h3>ç›¸é—œæ–‡ç»</h3>

<table>
<thead>
<tr>
<th>PMID</th>
<th>å¹´ä»½</th>
<th>æ¨™é¡Œ</th>
<th>ç›¸é—œæ€§</th>
</tr>
</thead>
<tbody>
<tr>
<td>-</td>
<td>-</td>
<td>(ç„¡ç›´æ¥é‡å°æ”è­·è…ºå°¿é“æ³Œå°¿ä¸Šçš®ç™Œçš„æ–‡ç»)</td>
<td>-</td>
</tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. kidney pelvis sarcomatoid transitional cell carcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.98%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. infiltrating bladder urothelial carcinoma sarcomatoid variant</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.98%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. renal pelvis papillary urothelial carcinoma</span>
<span class="evidence-badge evidence-L3">L3</span>
<span class="prediction-score">99.98%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ1 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03170960" target="_blank">NCT03170960</a></td><td>PHASE1</td><td>ACTIVE_NOT_RECRUITING</td><td>914</td><td>A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or i...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. uterine ligament adenocarcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.93%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. endocervical carcinoma</span>
<span class="evidence-badge evidence-L3">L3</span>
<span class="prediction-score">99.92%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ2 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03738228" target="_blank">NCT03738228</a></td><td>PHASE1</td><td>COMPLETED</td><td>40</td><td>Anti PD-L1 (Atezolizumab) as an Immune Primer and Concurrently With Extended Fie...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02921269" target="_blank">NCT02921269</a></td><td>PHASE2</td><td>COMPLETED</td><td>11</td><td>A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in P...</td></tr>
</tbody>
</table>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ1 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37467967/" target="_blank">37467967</a></td><td>2023</td><td>Article</td><td>Biomedical journal</td><td>Small cell neuroendocrine carcinoma of the cervix: From mole...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. adenoid cystic carcinoma of the cervix uteri</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.92%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. uterine ligament serous adenocarcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.92%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. signet ring cell variant cervical mucinous adenocarcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.91%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. intestinal variant cervical mucinous adenocarcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.91%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š
| è¨±å¯è­‰è™Ÿ | ä¸­æ–‡å“å | åŠ‘å‹ | è¨±å¯è­‰æŒæœ‰è€… | æ•ˆæœŸ |
|----------|----------|------|--------------|------|
| è¡›éƒ¨èŒç–«è¼¸å­—ç¬¬001050è™Ÿ | ç™Œè‡ªç¦¦ æ³¨å°„åŠ‘ | æ³¨å°„æ¶²åŠ‘ | ç¾…æ°å¤§è—¥å» è‚¡ä»½æœ‰é™å…¬å¸ | 2027/07/17 |
| è¡›éƒ¨èŒç–«è¼¸å­—ç¬¬001258è™Ÿ | ç™Œè‡ªç¦¦çš®ä¸‹æ³¨å°„åŠ‘ | çš®ä¸‹æ³¨å°„åŠ‘ | ç¾…æ°å¤§è—¥å» è‚¡ä»½æœ‰é™å…¬å¸ | 2029/05/29 |

## å®‰å…¨æ€§è€ƒé‡
- ä¸»è¦äº¤äº’ä½œç”¨ï¼šèˆ‡å…ç–«æŠ‘åˆ¶åŠ‘ (adalimumab, etanercept, infliximab, baricitinib ç­‰) ä½µç”¨ç‚º Major ç´šåˆ¥äº¤äº’ä½œç”¨
- é¡å›ºé†‡è—¥ç‰© (hydrocortisone, dexamethasone, prednisone ç­‰) ç‚º Moderate ç´šåˆ¥äº¤äº’ä½œç”¨ï¼Œå¯èƒ½é™ä½å…ç–«æ²»ç™‚æ•ˆæœ
- é¿å…èˆ‡æ´»ç–«è‹—ä½µç”¨
- éœ€ç›£æ¸¬å…ç–«ç›¸é—œä¸è‰¯åæ‡‰ï¼šè‚ºç‚ã€è‚ç‚ã€çµè…¸ç‚ã€ç”²ç‹€è…ºåŠŸèƒ½ç•°å¸¸ç­‰


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**Colitis** ğŸŸ¡ Moderate
- éœ€å®šæœŸç›£æ¸¬ã€‚å¯èƒ½æœ‰è‡´å‘½é¢¨éšªã€‚å‡ºç¾ç—‡ç‹€æ™‚æ‡‰è€ƒæ…®åœè—¥ã€‚

**è‚è‡Ÿç–¾ç—…** ğŸŸ¡ Moderate
- æ‡‰è¬¹æ…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚é€šå¸¸ç„¡éœ€èª¿æ•´åŠ‘é‡ã€‚å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚

**Pneumonia** ğŸŸ¡ Moderate
- éœ€å®šæœŸç›£æ¸¬ã€‚å¯èƒ½æœ‰è‡´å‘½é¢¨éšªã€‚å‡ºç¾ç—‡ç‹€æ™‚æ‡‰è€ƒæ…®åœè—¥ã€‚

**è…è‡Ÿç–¾ç—…** ğŸŸ¡ Moderate
- æ‡‰è¬¹æ…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚é€šå¸¸ç„¡éœ€èª¿æ•´åŠ‘é‡ã€‚å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚

**Endocrine System Diseases** ğŸŸ¢ Minor
- éœ€å®šæœŸç›£æ¸¬ã€‚å‡ºç¾ç—‡ç‹€æ™‚æ‡‰è€ƒæ…®åœè—¥ã€‚

**Hepatitis** ğŸŸ¢ Minor
- éœ€å®šæœŸç›£æ¸¬ã€‚å‡ºç¾ç—‡ç‹€æ™‚æ‡‰è€ƒæ…®åœè—¥ã€‚

**Infections** ğŸŸ¢ Minor
- éœ€å®šæœŸç›£æ¸¬ã€‚é¢¨éšªåŒ…æ‹¬ï¼šå‡ºè¡€ã€æ„ŸæŸ“ã€‚å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚å‡ºç¾ç—‡ç‹€æ™‚æ‡‰è€ƒæ…®åœè—¥ã€‚

**Meningitis** ğŸŸ¢ Minor
- éœ€å®šæœŸç›£æ¸¬ã€‚å‡ºç¾ç—‡ç‹€æ™‚æ‡‰è€ƒæ…®åœè—¥ã€‚

**Peripheral Nervous System Diseases** ğŸŸ¢ Minor
- éœ€å®šæœŸç›£æ¸¬ã€‚å‡ºç¾ç—‡ç‹€æ™‚æ‡‰è€ƒæ…®åœè—¥ã€‚

**Pancreatitis** ğŸŸ¢ Minor
- æ‡‰è¬¹æ…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚éœ€å®šæœŸç›£æ¸¬ã€‚å‡ºç¾ç—‡ç‹€æ™‚æ‡‰è€ƒæ…®åœè—¥ã€‚

## çµè«–èˆ‡ä¸‹ä¸€æ­¥
**æ±ºç­–ï¼šProceed**
**ç†ç”±ï¼š** Atezolizumab å·²åœ¨å¤šç¨®æ³Œå°¿ä¸Šçš®ç™Œä¸­å±•ç¾ç™‚æ•ˆï¼Œæ”è­·è…ºå°¿é“æ³Œå°¿ä¸Šçš®ç™Œå…·æœ‰ç›¸ä¼¼çš„è…«ç˜¤ç”Ÿç‰©å­¸ç‰¹æ€§ã€‚ç¾æœ‰ Phase 1/2 è‡¨åºŠè©¦é©—æ­£åœ¨è©•ä¼°å…¶åœ¨æ³Œå°¿ä¸Šçš®ç™Œçš„ç™‚æ•ˆï¼Œä¸”è—¥ç‰©å·²åœ¨å°ç£ä¸Šå¸‚ï¼Œå…·å‚™è‡¨åºŠä½¿ç”¨åŸºç¤ã€‚
**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
1. é—œæ³¨ NCT03170960 è©¦é©—ä¸­æ³Œå°¿ä¸Šçš®ç™Œäºçµ„çš„æœ€çµ‚çµæœ
2. è©•ä¼°æ˜¯å¦éœ€è¦é€²è¡Œå°ˆé–€é‡å°æ”è­·è…ºå°¿é“æ³Œå°¿ä¸Šçš®ç™Œçš„ Phase 2 è©¦é©—
3. æ”¶é›†çœŸå¯¦ä¸–ç•Œæ•¸æ“š (RWD) ä»¥æ”¯æŒé©æ‡‰ç—‡æ“´å±•

---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Pentoxifylline]({{ "/drugs/pentoxifylline/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Ethynodiol Diacetate]({{ "/drugs/ethynodiol_diacetate/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Butenafine]({{ "/drugs/butenafine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Tenofovir Alafenamide]({{ "/drugs/tenofovir_alafenamide/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Belimumab]({{ "/drugs/belimumab/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Atezolizumabè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/atezolizumab/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_atezolizumab,
  title = {Atezolizumabè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/atezolizumab/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
